paper
report
chemicoenzymat
synthesi
flcd
deriv
recognit
properti
deriv
test
use
floccul
yeast
isol
lectin
observ
substitut
flcyclodextrin
galactos
end
arm
induc
better
recognit
celllink
galactosespecif
lectin
physicochem
effect
flcd
deriv
membran
estim
use
red
blood
cell
effect
viabil
yeast
human
rectal
tumor
ceil
appreci
measur
mitochondri
deshydrogenas
activ
substitut
flcd
ring
sugar
antenna
decreas
neg
physicochem
effect
flcd
ie
hemolyt
properti
howev
substitut
induc
signific
modif
biolog
properti
molecul
particularli
cytotox
growth
eukaryot
cell
sugar
substitut
cyclodextrin
lectin
cell
recognit
cytotox
cyclodextrin
use
protect
drug
alter
conserv
use
fast
metabolis
upon
absorpt
patient
also
use
solubil
diluent
improv
properti
enhanc
bioavail
poorli
watersolubl
drug
cyclodextrin
may
also
use
transport
activ
deriv
specif
cellular
receptor
lectin
locat
cell
surfac
purpos
cyclodextrin
must
substitut
specif
ligand
lectin
order
improv
molecular
recognit
howev
last
year
demonstr
substitut
cyclodextrin
longer
biolog
amorph
compound
could
exhibit
biolog
activ
catalyt
properti
even
toxic
effect
effect
mainli
check
laboratori
anim
result
obtain
cell
cultur
recent
studi
demonstr
oligosaccharidyl
thioflcyclodextrin
good
recognit
capac
toward
yeast
galactos
specif
lectin
kb
cwl
especi
medium
length
hydrophob
spacer
set
termin
galactos
cyclodextrin
ring
paper
report
chemicoenzymat
synthesi
flcd
deriv
attempt
test
hemolyt
effect
activ
viabil
develop
eukaryot
cell
yeast
human
cell
line
chemic
flcyclodextrin
flcd
gift
wacker
gmbh
lyon
franc
dgal
lfuc
purchas
fluka
st
quentin
fallavi
franc
compound
galspflcd
fucspflcd
prepar
previous
describ
ihe
gicnacspom
kindli
donat
dr
charon
chatenaymalabri
franc
detail
synthesi
gicnacspflcd
galsp
flcd
publish
elsewher
deriv
solubl
distil
water
except
galsp
flcd
solubl
concentr
mgml
vv
mixtur
mixtur
effect
assay
deriv
steril
fdtration
membran
sartoriu
palaiseau
franc
use
follow
yeast
strain
use
kluyveromyc
bulgaricu
saccharomyc
cerevisia
uvarum
two
strain
floccul
inhibit
galactos
marmos
respect
yeast
cell
grown
aerob
air
flow
lh
h
liquid
medium
glucos
bactopepton
difco
michigan
usa
prolabo
pad
franc
contain
capac
fermentor
biolafitt
poissi
franc
human
rectal
adenocarcinoma
tumor
cell
line
obtain
laport
inra
jouyenjosa
franc
grown
rpmi
medium
without
lglutamin
phenol
red
icn
biomed
inc
costa
mesa
ca
usa
supplement
foetal
bovin
serum
life
technolog
eragni
franc
ofloxacin
roussel
uclaf
romainvil
franc
incub
day
humidifi
atmospher
contain
co
cell
gener
propag
upon
trypsin
treatment
percentag
cell
viabil
determin
trypan
blue
exclus
test
hrt
cell
contain
lectin
isol
treatment
deterg
mm
sodium
phosphat
buffer
ph
human
group
erythrocyt
rbc
wash
three
time
pb
buffer
mm
naci
mm
kci
mm
mm
mm
mm
caci
ph
resuspend
buffer
densiti
cellsml
maintain
use
extract
galactosespecif
lectin
perform
accord
ai
mahmood
et
al
ceil
harvest
centrifug
g
min
treat
galactos
extens
wash
phosphat
buffer
ph
cell
suspend
concentr
wv
buffer
contain
mm
edta
prolabo
pad
franc
incub
min
agit
centrifug
g
min
superuat
collect
dialyz
least
h
distil
water
lyophlliz
residu
floccul
activ
assess
helm
acet
buffer
mm
mm
mm
caci
mm
ph
necessari
cell
treat
twice
order
obtain
nonfloccul
ceil
yeast
cell
stationari
phase
harvest
wash
distil
water
mm
edta
aqueou
solut
twice
distil
water
wash
cell
mg
dri
weight
place
ml
helm
acet
buffer
ph
floccul
degre
fd
measur
accord
hussain
et
al
yeast
cell
suspend
vigor
shake
absorb
nm
immedi
measur
paus
min
absorb
suspens
measur
v
ratio
r
x
repres
percentag
cell
still
suspens
min
calcul
fd
estim
fd
associ
r
valu
defloccul
effect
flcd
deriv
fulli
floccul
yeast
estim
addit
differ
concentr
deriv
yeast
suspens
kb
cwl
lectin
dissolv
helm
buffer
titer
deriv
carbohydr
test
inhibitori
effect
dissolv
helm
buffer
concentr
inhibit
hemagglutin
lectin
solut
dilut
serial
twofold
dilut
introduc
microtit
plate
nunc
kamstrup
denmark
equal
volum
select
deriv
carbohydr
appropri
concentr
ad
mixtur
incub
rain
room
temperatur
mild
agit
trypsintr
erythrocyt
suspens
human
blood
group
ad
incub
rain
room
temperatur
agglutin
examin
inhibitori
activ
express
minimum
concentr
inhibitor
effect
maxim
inhibit
hemagglutin
test
nonfloccul
yeast
cell
glass
tube
use
instead
microtit
plate
control
buffer
alon
ad
instead
inhibitor
solut
determin
effect
flcd
flcd
deriv
viabil
eukaryoti
cell
line
cultur
perform
evalu
inhibit
cell
prolifer
measur
mitochondri
deshydrogenas
activ
assay
activ
mitochondri
succin
deshydrogenas
live
hrtceil
caus
cleavag
convers
solubl
yellow
tetrazolium
solut
f
diphenyl
tetrazolium
bromid
sigma
saint
loui
mo
usa
insolubl
purpl
formazan
dead
cell
caus
chang
cellular
viabil
evalu
modifi
mtr
follow
techniqu
carmichael
et
al
nonconflu
cell
grown
flat
bottom
cultur
plate
costar
cambridg
usa
cell
per
well
treat
variou
concentr
flcd
deriv
h
end
incub
period
ceil
wash
rpmipr
phenol
redfre
rpmi
mgml
solut
mtt
rpmiprmedium
without
foetal
calf
serum
ad
well
h
incub
medium
remov
insolubl
blue
formazan
product
dissolv
dmso
sigma
saint
loui
mo
usa
absorb
solubil
materi
measur
spectrophotometr
nm
nm
titertek
multiscan
mk
ii
apparatu
labsystem
helsinki
finland
express
function
concentr
convert
dye
result
shown
averag
valu
experi
done
triplic
cytotox
effect
correspond
decreas
purpl
formazan
product
determin
effect
flcd
flcd
deriv
yeast
perform
evalu
cell
growth
mitochondri
deshydrogenas
activ
follow
techniqu
carmichael
et
al
slightli
modifi
assay
perform
microtit
plate
growth
evalu
yeast
suspens
cellsml
incub
h
stir
absorb
measur
nm
titertek
multiscan
mk
ii
apparatu
labsystem
helsinki
finland
cultur
assay
perform
least
four
well
mitochondri
deshydrogenas
activ
appropri
cyclodextrin
dilut
cultur
medium
mix
yeast
suspens
cellsml
incub
h
agit
plate
centrifug
min
rpm
supernat
discard
mtt
mgml
solut
cultur
medium
ad
well
plate
agit
incub
h
centrifug
supernat
discard
insolubl
blue
formazan
product
dissolv
dmso
sigma
saint
loui
mo
usa
absorb
measur
nm
nm
titertek
multiscan
mk
ii
apparatu
assay
also
perform
rest
cell
khzpo
ph
instead
cultur
medium
presenc
methyl
galactosid
galactos
mannos
concentr
ram
toxic
stimulatori
effect
yeast
correspond
decreas
increas
formazan
product
respect
human
erythrocyt
freshli
drawn
blood
suppli
ct
nanci
franc
hemolyt
effect
determin
flcyclodextrin
deriv
perform
mix
serial
dilut
cyclodextrin
deriv
pb
human
group
erythrocyt
rbc
suspens
final
red
blood
cell
concentr
cellsml
incub
card
slight
agit
min
incub
suspens
centrifug
g
min
optic
densiti
supernat
measur
hemoglobin
nm
percentag
hemolysi
evalu
versu
hemolyz
erythrocyt
suspens
erythrocyt
suspensiondistil
water
vv
modif
concern
substitut
reactiv
primari
hydroxyl
face
gaispflcd
fucspflcd
glcnacspflcd
deriv
obtain
via
peptid
coupl
respect
saccharidespacercarboxyl
acid
deriv
obtain
reduct
monoazido
compound
coupl
carri
soft
condit
use
dcchobt
activ
system
similar
condit
use
galsp
flcd
full
substitut
achiev
stereospecif
transfer
fldgal
group
glcnacspflcd
udp
gener
situ
udpglc
achiev
use
galactosyl
transferas
give
high
yield
desir
lactosylamino
deriv
synthesi
describ
detail
elsewher
use
epimeras
allow
avoid
extrem
expens
udpgal
consum
next
step
affect
overal
yield
synthesi
differ
deriv
use
test
present
tabl
floccul
degre
fulli
floccul
yeast
evalu
helm
acet
buffer
accord
procedur
describ
hussain
et
al
condit
floccul
degre
k
bulgaricu
cerevisia
estim
respect
tabl
report
defloccul
effect
flcd
deriv
fulli
floccul
yeast
result
show
defloccul
effect
cerevisia
floccul
involv
mannosespecif
lectin
k
bulgaricu
floccul
involv
galactosespecif
lectin
effici
deriv
fucspflcd
weaker
activ
galspflcd
galsp
flcd
may
result
lower
watersolubl
former
flcd
product
glcnacspom
bear
galactos
residu
present
lower
even
activ
shown
kb
cwl
lectin
induc
group
red
blood
cell
rbc
agglutin
well
k
bulgaricu
floccul
galactos
deriv
inhibit
agglutin
floccul
effect
flcd
deriv
use
inhibitor
kb
cwl
lectin
agglutin
activ
rbc
previous
defloccul
k
bulgaricu
yeast
cell
parallel
inhibit
effect
observ
test
inde
report
tabl
gaispflcd
effici
either
red
blood
cell
yeast
floccul
unsubstitut
flcd
glcnacspflcd
glcnacspom
effect
k
bulgaricu
floccul
compound
present
howev
inhibitori
activ
hemagglutin
slightli
less
effici
galactos
flcd
deriv
tion
ring
strongli
diminish
hemolyt
properti
flcyclodextrin
ring
substitut
galactos
fulli
substitut
gal
arm
hemolyt
activ
three
time
lower
natur
flcd
deriv
hemolyt
activ
much
weaker
effect
flcd
deriv
cellular
viabil
nonconflu
cell
evalu
h
treatment
mtt
assay
describ
materi
method
must
note
natur
flcd
affect
cellular
viabil
concentr
test
ram
h
period
compar
untreat
ceil
contrari
flcd
deriv
exhibit
inhibit
effect
mitochondri
deshydrogenas
activ
hrtcell
figur
signific
cytotox
effect
observ
decreas
cell
viabil
presenc
mm
gicnacspflcd
fucspflcd
decreas
mm
howev
mitochondri
enzymat
activ
cell
poorli
affect
presenc
glcnac
decreas
observ
highest
concentr
test
ram
result
obtain
flcd
deriv
bear
galactos
arm
shown
figur
cyto
tabl
defloccul
effect
flcd
sugar
deriv
fulli
floccul
k
bulgaricu
cerevisia
cell
result
express
mm
minimum
concentr
defloccul
fulli
floccul
yeast
degre
floccul
measur
follow
procedur
describ
hussain
et
al
k
bulgaricu
fd
cerevisia
var
uvarum
fd
effect
detect
mm
flcd
deriv
sd
k
bulgaricu
cell
grown
presenc
flcd
galspflcd
toxic
effect
could
observ
observ
instead
shown
figur
increas
deshydrogenas
activ
mtt
test
concomit
increas
cell
growth
effect
observ
substitut
flcd
ring
bear
gal
arm
free
flcd
ring
well
free
arm
much
lower
effect
cerevisia
yeast
cell
grown
condit
fig
signific
effect
observ
neither
growth
mtt
activ
order
control
whether
stimul
relat
recognit
process
galspflcd
galactos
specif
lectin
k
bulgaricu
effect
latter
deriv
test
rest
yeast
cell
test
perform
presenc
mannos
galactos
methyl
galactosid
shown
figur
galspflcd
enhanc
deshydrogenas
activ
k
bulgaricu
test
perform
presenc
mannos
activ
affect
presenc
methyl
galactosid
galactos
activ
diminish
respect
indic
competit
gaispflcd
galactos
deriv
recognit
site
yeast
lectin
flcd
ring
bear
galactos
arm
effect
mtt
activ
observ
fig
result
express
percentag
variat
versu
control
assay
without
deriv
one
limit
applic
natur
cyclodextrin
medic
situat
relat
physicochem
properti
solubl
hemolyt
activ
particularli
import
case
flcyclodextrin
sever
chemic
modif
propos
mani
differ
purpos
decreas
cytotox
effect
improv
solubl
recognit
phenomenon
result
show
chemic
modif
flcd
substitut
primari
hydroxyl
ring
galactos
end
arm
induc
recognit
carbohydr
recognit
protein
inde
galactosespecif
lectin
provok
yeast
aggreg
hemagglutin
inhibit
galactos
substitut
flcd
furthermor
recognit
specif
galactosespecif
lectin
inhibit
deriv
mannosespecif
one
flcd
suffici
high
concentr
caus
hemolysi
observ
substitut
flcd
weaker
hemolyt
activ
unsubstitut
flcd
although
chemic
structur
substitut
differ
studi
yamamoto
et
al
result
agreement
data
author
nevertheless
chemic
modif
cyclodextrin
ring
decreas
hemolyt
properti
iti
cyclodextrin
carrier
enhanc
anticellular
activ
antineoplas
drug
revers
multidrug
resist
evalu
effect
cyclodextrin
deriv
pglycoproteinposit
mdr
cell
line
human
rectal
adenocarcinoma
cell
line
nativ
cd
concentr
rang
mm
h
exposur
time
effect
deshydrogenas
activ
human
cell
line
grown
cell
cultur
contain
foetal
calf
serum
howev
sugar
substitut
flcd
ring
saccharid
antenna
glcnac
galactos
fucos
signific
cytotox
effect
cell
mm
molecul
maximum
recommend
concentr
h
exposur
pitha
propos
limit
use
exposur
h
cell
grown
serumfre
media
cyclodextrin
may
use
without
limit
exposur
time
media
contain
serum
flcd
deriv
galspflcd
present
cultur
yeast
k
bulgaricu
also
bear
galactosespecif
lectin
surfac
increas
growth
cell
deshydrogenas
activ
shown
increas
absorb
cell
suspens
increas
formazan
format
higher
deshydrogenas
activ
result
growth
increas
sinc
activ
strongli
enhanc
test
achiev
rest
cell
phosphat
buffer
without
nitrogen
sourc
phenomenon
appear
specif
galactos
deriv
diminish
effect
ii
effect
observ
uvarum
bear
mannos
specif
lectin
iii
free
flcd
without
galactos
arm
stimulatori
effect
last
case
toxic
effect
may
observ
way
deriv
affect
intracellular
mitochondri
succin
deshydrogenas
activ
remain
demonstr
substitut
ring
galactos
arm
improv
recognit
process
peripher
cell
receptor
also
exclud
deriv
associ
cell
surfac
lectin
may
activ
transmembran
molecul
induc
cellular
reaction
studi
achiev
confirm
hypothesi
